Holen Sie sich die Stockscreener-App
8.50
5.26%
0.425
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Cathie Wood’s ARK Buys Intellia, Nextdoor, Sells Block Stock - Investing.com
Crispr Therapeutics Products 2025: Therapies, MOA Insights, - openPR.com
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High? - Yahoo Finance
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.1% After Analyst Downgrade - Defense World
Transcript : Intellia Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04 - marketscreener.com
(NTLA) Technical Data - news.stocktradersdaily.com
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $45.00 by Analysts at Guggenheim - Defense World
Forecasting The Future: 11 Analyst Projections For Intellia Therapeutics - Benzinga
Guggenheim Maintains 'Buy' Rating on NTLA, Lowers Price Target | - GuruFocus
Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade) - Seeking Alpha
Guggenheim cuts Intellia stock price target to $45, maintains buy By Investing.com - Investing.com India
Intellia Therapeutics (NTLA) Price Target Cut to $45 by Guggenhe - GuruFocus
Intellia Therapeutics Inc (NASDAQ: NTLA) – An Analysis Is What You Need - Stocksregister
Intellia Therapeutics’ (NTLA) Buy Rating Reiterated at Chardan Capital - Defense World
Analysts Have Made A Financial Statement On Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) First-Quarter Report - simplywall.st
Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report - Yahoo Finance
Industry Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts - simplywall.st
News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts - Yahoo Finance
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2025 Earnings Call Transcript - Insider Monkey
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up - TradingView
Truist Securities Cuts Price Target on Intellia Therapeutics to $33 From $50, Maintains Buy Rating - marketscreener.com
Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid Revenue Decline - GuruFocus
Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Intellia Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Transcript : Intellia Therapeutics, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Intellia Therapeutics (NTLA) Price Target Reduced Amid Market Challenges | NTLA Stock News - GuruFocus
Intellia Therapeutics (NTLA) Advances in 2025 with Key Milestones - GuruFocus
Earnings call transcript: Intellia Therapeutics beats EPS and revenue forecasts in Q1 2025 - Investing.com
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Intellia Therapeutics Inc earnings beat by $0.17, revenue topped estimates - Investing.com
NTLA Financial Outlook: Cash Reserves and Future Funding | NTLA Stock News - GuruFocus
Intellia (NTLA) Surpasses Revenue Expectations and Advances Clinical Programs | NTLA Stock News - GuruFocus
Intellia Therapeutics (NTLA) Q1 2025 Earnings: EPS of -$1.10 Beats Estimates, Revenue Surpasses Expectations at $16.6 Million - GuruFocus
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress | NTLA Stock News - GuruFocus
Intellia Therapeutics Reports Progress in Phase 3 Trials for Hereditary Angioedema and ATTR Amyloidosis, Highlights Financials for Q1 2025 - Nasdaq
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Gene Editing Leader Intellia Therapeutics Expands Team with 69,600 Share Inducement Grant - Stock Titan
Long-Term Investors in shares of Intellia Therapeutics, Inc. - openPR.com
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Genome Editing Market Future Business Opportunities 2025-2032 - openPR.com
Genome Engineering Market Generated Opportunities, Future - openPR.com
(NTLA) Long Term Investment Analysis - news.stocktradersdaily.com
Intellia Therapeutics Inc (NTLA) Has Recovered 31.71% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
Intellia Therapeutics Inc [NTLA] Records 200-Day SMA of $15.05 - knoxdaily.com
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates - The Manila Times
Leading CRISPR Pioneer Intellia Therapeutics to Reveal Q1 2025 Financial Results and Pipeline Updates - Stock Titan
The growth track for Intellia Therapeutics Inc (NTLA) has changed recently - Sete News
Company’s Banking Stock: Dissecting a -16.35% Quarterly Revenue Decline Amid Growth - investchronicle.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Intellia Therapeutics Inc’s results are impressive - uspostnews.com
Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet - Yahoo Finance
Upward Trajectory: Intellia Therapeutics Inc (NTLA) Posts a Gaine, Closing at 8.48 - DWinneX
Intellia Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com
Legal & General Group Plc Buys 10,211 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - The AM Reporter
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):